checkAd

     117  0 Kommentare Insulet to Present Results from First Omnipod 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

    Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, will present new clinical evidence related to the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place March 6 – 9, 2024 in Florence, Italy, and online.

    “We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director. “This evidence further demonstrates the superiority of Omnipod 5 for people with diabetes and validates the importance of AID as the standard of care worldwide. Completion of this trial represents a key step forward in increasing global access to this technology.”

    The OP5-003 international randomized controlled trial results will be presented by Professor Eric Renard, MD, PhD of Montpellier University Hospital on Friday, March 8. Professor Renard will present evidence of the efficacy and safety of the automated Omnipod 5 System compared to insulin pump therapy with a continuous glucose monitoring (CGM) in adults with type 1 diabetes in the United States and France. It is the first Omnipod 5 randomized controlled trial to date, and the first time the system has been evaluated in participants living outside of the United States.

    Omnipod 5 Real-World Evidence will also be shared during an oral presentation on Saturday, March 9 by Dr. Fraser Gibb, PhD FRCP Consultant Physician, Edinburgh Centre for Endocrinology & Diabetes and Honorary Clinical Reader, University of Edinburgh UK, as well as through three poster presentations.

    “The Omnipod 5 Real-World Evidence database continues to provide a wealth of information for healthcare providers looking to understand the system’s performance and optimization under real-world conditions,” said Dr. Gibb. “Insulet’s tubeless AID innovation is having a remarkable impact on people with diabetes across all age groups with diverse insulin needs. The importance of this database and the insights it provides healthcare providers cannot be overstated.”

    With data on more than 100,000 users in the U.S. now available, Dr. Gibb and others will share new insights, including outcomes for those using the system for more than one year, data on users with low insulin requirements, and how the system responds to a missed meal bolus in the real world.

    Seite 1 von 4



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Insulet to Present Results from First Omnipod 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, will present new clinical evidence related to the Omnipod 5 Automated Insulin Delivery System …